Sforzin Isabella, Borad Mitesh, Uson Junior Pedro Luiz Serrano
Center for Personalized Medicine, Hospital Israelita Albert Einstein, São Paulo 05652900, Brazil.
Division of Hematology-Oncology, Department of Medicine, Mayo Clinic Arizona, Mayo Clinic Cancer Center, Phoenix, AZ 85054, United States.
World J Gastrointest Oncol. 2024 Nov 15;16(11):4522-4527. doi: 10.4251/wjgo.v16.i11.4522.
Colorectal cancer (CRC) is a type of cancer that grows from polypoid lesions developing over the years. It has a high incidence of about 1.8 million new cases annually. While screening and lifestyle modifications have stabilized the rate of CRC in high-income countries, the incidence of early-onset CRC is increasing globally. The worst prognosis for this cancer is linked to recurrence and metastasis, with peritoneal metastasis occurring in 8% to 20% of cases. In these cases, treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is indicated. However, this approach is risky and requires careful selection of patients who will truly benefit from it. This article will discuss the correlation between nutrition and inflammation in patients with peritoneal metastasis and advanced CRC, emphasizing the importance of nutritional and inflammatory markers for assessing disease status. Finally, we will highlight the main biomarkers in the field.
结直肠癌（CRC）是一种由多年来发展形成的息肉样病变引发的癌症。其发病率很高，每年约有180万新发病例。虽然筛查和生活方式的改变已使高收入国家的CRC发病率趋于稳定，但全球范围内早发性CRC的发病率正在上升。这种癌症最糟糕的预后与复发和转移有关，8%至20%的病例会发生腹膜转移。在这些病例中，需要进行细胞减灭术和腹腔内热灌注化疗。然而，这种方法风险较大，需要仔细挑选真正能从中受益的患者。本文将探讨腹膜转移和晚期CRC患者营养与炎症之间的相关性，强调营养和炎症标志物对评估疾病状态的重要性。最后，我们将重点介绍该领域的主要生物标志物。
